Ultra-early administration of eculizumab in a child with atypical hemolytic uremic syndrome: a case report.
10.7499/j.issn.1008-8830.2503084
- Author:
Dan-Dan GUO
1
;
Yi-Xin XIAO
1
;
Wei-Rui WANG
1
;
Xiao-Lu DENG
1
;
Ye-Hong HUANG
1
Author Information
1. Department of Pediatrics, Xiangya Hospital of Central South University, Changsha 410008, China.
- Publication Type:English Abstract
- Keywords:
Atypical hemolytic uremic syndrome;
Child;
Eculizumab;
Ultra-early therapy
- MeSH:
Humans;
Antibodies, Monoclonal, Humanized/administration & dosage*;
Female;
Atypical Hemolytic Uremic Syndrome/drug therapy*;
Child;
Complement C3b Inactivator Proteins
- From:
Chinese Journal of Contemporary Pediatrics
2025;27(11):1408-1413
- CountryChina
- Language:Chinese
-
Abstract:
A 10-year-old girl was admitted with a 38-hour history of widespread subcutaneous petechiae and hematuria and a 6-hour history of jaundice and oliguria. Physical examination revealed widespread subcutaneous petechiae and jaundice of the skin and sclera. Laboratory tests showed anemia, thrombocytopenia, acute kidney injury, and markedly elevated lactate dehydrogenase. Thrombotic microangiopathy was initially diagnosed, with a high suspicion of atypical hemolytic uremic syndrome (aHUS). Eculizumab was initiated within 9 hours of admission (within 48 hours of onset). After the first infusion, hemolysis rapidly ceased, and the platelet count and renal function gradually returned to normal. Whole-exome sequencing identified homozygous deletions of CFHR1 exon 2 and CFHR4 exon 1. aHUS typically has abrupt onset and rapid progression. Clinicians should maintain high suspicion for aHUS when the triad of thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney injury is present. Ultra-early eculizumab (within 48 hours of onset) rapidly blocks complement-mediated thrombotic microangiopathy, reverses organ injury, and improves long-term prognosis. Additionally, complement-related genetic testing is important for etiological clarification and individualized determination of eculizumab treatment duration.
